GSK lifts full-year outlook as Q2 sales rise
27th Jul 2022 07:21
(Sharecast News) - GlaxoSmithKline lifted its full-year outlook on Wednesday as it posted a jump in second-quarter sales.
Read moreCiti starts GSK spinoff Haleon at 'buy'
21st Jul 2022 07:26
(Sharecast News) - Citi initiated coverage of Haleon - GlaxoSmithKline's consumer health spinoff - on Thursday with a 'buy' rating and 360p price target.
Read moreGSK spins off consumer healthcare giant Haleon
18th Jul 2022 12:12
(Sharecast News) - GSK has spun off its consumer healthcare arm Haleon in Europe's largest listing for more than a decade.
Read moreCovid-19 cases surge during latest week due to BA.4 and BA.5 Covid-19 sub-variants
1st Jul 2022 13:22
(Sharecast News) - The number of new coronavirus cases in Britain jumped again during the preceding week, likely due to the more infectious BA.4 and BA.5 variants of the Omicron variant of Covid-19.
Read moreGSK submits shingles vaccine application in Japan for over 18s
28th Jun 2022 07:25
(Sharecast News) - Pharma giant GlaxoSmithKline on Tuesday said it had submitted a regulatory application Japan's Ministry of Health, Labour and Welfare (MHLW) for its Shingrix shingles vaccine for adults aged 18 years and older who are at increased risk.
Read moreGlaxoSmithKline to invest £1bn in infectious disease R&D
23rd Jun 2022 14:18
(Sharecast News) - GlaxoSmithKline said on Thursday it will invest £1bn over ten years to accelerate research and development (R&D) into infectious diseases that disproportionately impact lower-income countries.
Read moreGSK says respiratory vaccine shows 'significant' efficacy in trial
10th Jun 2022 07:03
(Sharecast News) - GlaxoSmithKline said its vaccine for respiratory virus had shown "statistically significant" and clinically meaningful efficacy in adults aged 60 years and above in a phase 3 trial.
Read moreGSK's MMR vaccine Priorix gets US FDA approval
6th Jun 2022 07:57
(Sharecast News) - GlaxoSmithKline said on Monday that the US Food and Drug Administration has approved its Priorix vaccine for measles, mumps and rubella in people aged 12 months and older.
Read moreGlaxoSmithKline to acquire US biopharmaceutical firm Affinivax
31st May 2022 07:06
(Sharecast News) - Drugmaker GlaxoSmithKline said on Tuesday that it had agreed to acquire Boston-based clinical-stage biopharmaceutical company Affinivax as part of a deal valued at as much as $3.3bn.
Read moreGlaxoSmithKline nears deal to build £400m science campus in Hertfordshire
30th May 2022 08:30
(Sharecast News) - Drugmaker GlaxoSmithKline was said to be nearing a deal to build a £400.0m science campus in Hertfordshire that could create as many as 5,000 highly skilled jobs over the next decade.
Read moreChina approves two-dose schedule for GSK's cervical cancer drug
27th May 2022 07:02
(Sharecast News) - UK pharma giant GSK said China's National Medical Products Administration has approved a two-dose vaccine schedule for its Cervarix treatment in girls aged between 9 to 14 years for the prevention of cervical cancer.
Read moreGSK sales top forecasts
27th Apr 2022 08:54
(Sharecast News) - GlaxoSmithKline posted above-forecast numbers on Wednesday, boosted by strong demand for its Covid-19 drug.
Read moreUS FDA accepts GSK application for kidney disease drug
19th Apr 2022 07:31
(Sharecast News) - GlaxoSmithKline said the US Food and Drug Administration (FDA) had accepted its application for its chronic kidney disease drug daprodustat.
Read moreGSK agrees to buy Sierra Oncology for $1.9bn
13th Apr 2022 07:17
(Sharecast News) - GlaxoSmithKline has agreed to buy Sierra Oncology, a US rare cancer therapy company, for $1.9bn (£1.5bn) in cash to add to its roster of specialty medicines and vaccines.
Read moreGSK's Cabenuva receives approved label update from FDA
24th Mar 2022 15:06
(Sharecast News) - Pharmaceutical company GlaxoSmithKline revealed on Thursday that ViiV Healthcare, its HIV venture with Pfizer and Shionogi, has received an approved label update from the Food and Drug Administration for its Cabenuva asset.
Read more